MRNA-1273

Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 3, 2022
Investment, World, RNA, Assembly, Hepatitis B, COVID-19, Hepatitis, Cornerstone, Partnership, Nasdaq, CccDNA, Patent, CFBV, Method, Therapy, RNA interference, Company, Clinical trial, District, Virology, Severe acute respiratory syndrome coronavirus 2, World Health Organization, HBsAg, Research, Peripheral neuropathy, Douglas v. U.S. District Court ex rel Talk America, MRNA-1273, Degenerative disease, Sale, HBV, VBR, Coronavirus, Immune system, NA, Patient, Hospital, Safety, LNP, Membrane protein, Travel, Arbutus, District court, GLOBE, Vaccine, Pharmaceutical industry, Construction, Geneve 9640, Vaccitech, IND, Roivant Sciences, Tenofovir disoproxil

WARMINSTER,Pa., March 03, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its fourth quarter and year end 2021 financial results and provides pipeline updates.

Key Points: 
  • WARMINSTER,Pa., March 03, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its fourth quarter and year end 2021 financial results and provides pipeline updates.
  • 2021 was a transformative year for Arbutus as we greatly expanded our development efforts in Hepatitis B and coronavirus infections, including SARS-CoV-2, said William Collier, Arbutus President and Chief Executive Officer.
  • Arbutus has commenced IND-enabling studies for AB-101 and intends to complete those studies in the second half of 2022.
  • Arbutus, and Genevant, do not seek an injunction or otherwise seek to impede the sale, manufacture or distribution of MRNA-1273.

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna

Retrieved on: 
Monday, February 28, 2022
GLOBE, Therapy, RNA transfection, Patent, Method, Coronavirus, Risk, Securities Exchange Act of 1934, RNA, Hepatitis B virus, IPR, United States Court of Appeals for the Federal Circuit, Immune system, Annual report, District, Carla Geneve, COVID-19, HBV, PD, Virology, Sale, LNP, MRNA-1273, MRNA, Douglas v. U.S. District Court ex rel Talk America, Complaint, Travel, District court, Severe acute respiratory syndrome coronavirus 2, RNA interference, Securities Act of 1933, Nasdaq, Forward-looking statement, Drug discovery, Patient, Technology, CEO, Program, Degenerative disease, Vaccine, Pharmaceutical industry, Security (finance), Moderna, Arbutus

William Collier, President and CEO of Arbutus, stated, Arbutus and its licensee Genevant do not seek an injunction or otherwise seek to impede the sale, manufacture or distribution of MRNA-1273.

Key Points: 
  • William Collier, President and CEO of Arbutus, stated, Arbutus and its licensee Genevant do not seek an injunction or otherwise seek to impede the sale, manufacture or distribution of MRNA-1273.
  • Scientists at Arbutus and Genevant have spent years developing and refining lipid nanoparticle (LNP) delivery technology, which has been licensed for various applications to many different third parties.
  • Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases.
  • Forward-looking statements in this press release include statements about the patent infringement lawsuit against Moderna and our future development plans for our product candidates.

Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda

Retrieved on: 
Thursday, January 21, 2021
Biotechnology, Infectious diseases, Other Health, Health, Pharmaceutical, Medicine, Medical research, Health sciences, Articles, Clinical trials, COVID-19 vaccine, MRNA-1273, Moderna, Vaccine, Tozinameran, RNA vaccine

(Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in the Phase 1/2 study of Modernas vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co., Ltd (NYSE: TAK).

Key Points: 
  • (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in the Phase 1/2 study of Modernas vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co., Ltd (NYSE: TAK).
  • We are pleased that this Phase 1/2 study of our COVID-19 vaccine in healthy adults in Japan has begun.
  • This placebo-controlled Phase 1/2 study will evaluate the safety and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart.
  • Takeda and Moderna previously announced that Takeda will import and distribute 50 million doses of Modernas COVID-19 vaccine candidate starting in the first half of 2021, pending licensure in Japan.

Beacon Christian Community Health Shows How It's Done With Its Successful Moderna COVID-19 Vaccination Program

Retrieved on: 
Wednesday, January 13, 2021
Clinical trials, COVID-19 vaccine, Medical research, MRNA-1273, Medicine, Health sciences, Articles

Beacon Health received its first allocation of the Moderna COVID-19 Vaccine on Monday, December 21, 2020, and successfully administered 10% of that week's allocation on Wednesday, December 23, 2020.

Key Points: 
  • Beacon Health received its first allocation of the Moderna COVID-19 Vaccine on Monday, December 21, 2020, and successfully administered 10% of that week's allocation on Wednesday, December 23, 2020.
  • Dr. Allan Perel, MD, Chief of Neurology, Richmond University Medical Center recently said, "Beacon has been a godsend for my office.
  • Staff members and I at Alpha Neurology Medical Practice have shared just how wonderful Beacon Health as a whole, especially Drs.
  • Beaconis a faith-based community health center which provides care to Mariners Harbor and Staten Island residents.

Publix and the State of Florida Expand COVID‑19 Vaccinations to an Additional 27 Store Pharmacies and Five Counties

Retrieved on: 
Tuesday, January 12, 2021
Other Consumer, Health, Supermarket, Women, Seniors, Pharmaceutical, MEN, Infectious diseases, Retail, Family, Consumer, Florida, Regions of the United States, Publix, Florida Republicans, Ron DeSantis, DeSantis, COVID-19 vaccine, Vaccine, The Villages, Florida, MRNA-1273

Publix, in collaboration with Florida Governor Ron DeSantis, will begin providing COVID19 vaccinations in five additional Florida counties and The Villages in Marion County starting Thursday, Jan. 14.

Key Points: 
  • Publix, in collaboration with Florida Governor Ron DeSantis, will begin providing COVID19 vaccinations in five additional Florida counties and The Villages in Marion County starting Thursday, Jan. 14.
  • The expansion comes as Governor DeSantis has provided Publix with additional doses of the Moderna vaccine to be administered to individuals ages 65 and older.
  • With todays announcement, Publix is adding 27 pharmacies to the list of those currently offering vaccinations, bringing the total number of Publix pharmacies offering COVID-19 vaccinations to 49.
  • For 90 years, Publix has served its customers and communities in times of need, said Publix CEO Todd Jones.

Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland

Retrieved on: 
Tuesday, January 12, 2021
Health, Infectious diseases, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Medicine, Medical research, Health sciences, Articles, Clinical trials, RNA, MRNA-1273, Vaccines, COVID-19 vaccine, Moderna, RNA vaccine, Vaccine, the COVID-19 Vaccine Moderna, Moderna

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the COVID-19 Moderna Vaccine in Switzerland.

Key Points: 
  • Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the COVID-19 Moderna Vaccine in Switzerland.
  • Having our COVID-19 Vaccine Moderna authorized in Switzerland is an important milestone for us, said Stphane Bancel, Chief Executive Officer of Moderna.
  • The Swiss Federal Government has secured 7.5 million doses of the COVID-19 Vaccine Moderna.
  • The COVID-19 Vaccine Moderna (referred to in the U.S. as the Moderna COVID-19 Vaccine) is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.

Luminare Partners With the City of Corpus Christi To Deploy Innoculate™ - A COVID-19 Vaccine Management Solution

Retrieved on: 
Friday, January 8, 2021
Medicine, Health sciences, Health, Clinical trials, RNA, RNA vaccine, Vaccines, COVID-19 vaccine, Vaccine, MRNA-1273, Corpus Christi, Texas

HOUSTON, Jan. 8, 2021 /PRNewswire/ -- Luminare has partnered with the City of Corpus Christi to deploy Innoculate, an automated COVID-19 vaccine management solution.

Key Points: 
  • HOUSTON, Jan. 8, 2021 /PRNewswire/ -- Luminare has partnered with the City of Corpus Christi to deploy Innoculate, an automated COVID-19 vaccine management solution.
  • The Corpus Christi Nueces County Public Health District was recently notified that it will receive 4,000 Moderna vaccines that will be administered through a mega COVID-19 vaccine drive thru .
  • We're excited to partner with Luminare in distributing vaccines to the citizens of Corpus Christi.
  • Luminare developed Quickscreen, an innovative COVID-19 screening tool to help people get back to work and keep businesses safe.

Research Centers of America Expedite Broad Study on Moderna's COVID-19 Vaccine

Retrieved on: 
Thursday, January 7, 2021
Medicine, Health sciences, Medical research, Health, Virology, Clinical trials, MRNA-1273, COVID-19 vaccine, Vaccine, Moderna, Tozinameran, Inovio Pharmaceuticals

HOLLYWOOD, Fla., Jan. 7, 2021 /PRNewswire/ --Research Centers of America (" RCA "), a CenExel Center of Excellence,joined nearly 100 other clinical research facilities across the United States to test the safety and efficacy of Moderna's mRNA-1273 vaccine against COVID-19.

Key Points: 
  • HOLLYWOOD, Fla., Jan. 7, 2021 /PRNewswire/ --Research Centers of America (" RCA "), a CenExel Center of Excellence,joined nearly 100 other clinical research facilities across the United States to test the safety and efficacy of Moderna's mRNA-1273 vaccine against COVID-19.
  • "The data demonstrated strong safety and efficacy results from a novel mRNA COVID-19 vaccine," he said.
  • "In the past several years, our Centers have supported over 100 vaccine trials and surpassed recruitment goals by 110%.
  • The CenExel Centers of Excellence deliver the engagement, expertise, and results to ensure that their clients achieve their clinical research goals.

Correctional Service Canada COVID-19 Vaccine Roll-out

Retrieved on: 
Wednesday, January 6, 2021
Government of Canada, Articles, Medicine, Clinical trials, Health Canada, Public Health Agency of Canada, MRNA-1273, Correctional Service of Canada, Vaccines, COVID-19 vaccine

CSC expects to begin the rollout of vaccinations to highest-risk inmates in federal correctional institutions starting on January 8, 2021.

Key Points: 
  • CSC expects to begin the rollout of vaccinations to highest-risk inmates in federal correctional institutions starting on January 8, 2021.
  • As further supply of the vaccine becomes available, it will eventually be offered to all federal inmates based on NACI prioritization guidance.
  • CSC has been working closely with the Public Health Agency of Canada (PHAC) and has begun receiving doses of the Moderna vaccine, which was recently approved by Health Canada.
  • "The health and safety of our employees, inmates, and the public is a top priority for the Correctional Service of Canada.

European Commission Authorizes COVID-19 Vaccine Moderna in Europe

Retrieved on: 
Wednesday, January 6, 2021
Other Health, General Health, Pharmaceutical, Oncology, Medical devices, Infectious diseases, Hospitals, Clinical trials, Biotechnology, Medical Supplies, FDA, Practice Management, Health, Medicine, Health sciences, Medical research, Articles, Clinical trials, RNA, COVID-19 vaccine, MRNA-1273, Moderna, RNA vaccine, Vaccine, Coronavirus disease, the COVID-19 Vaccine Moderna, Moderna

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission has granted a conditional marketing authorization (CMA) for COVID-19 Vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union.

Key Points: 
  • Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission has granted a conditional marketing authorization (CMA) for COVID-19 Vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union.
  • The first deliveries of COVID-19 Vaccine Moderna to European countries from Modernas dedicated non-U.S. supply chain are expected to begin next week.
  • The COVID-19 Vaccine Moderna (referred to in the U.S. as the Moderna COVID-19 Vaccine) is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.
  • The COVID-19 Vaccine Moderna has been granted a Conditional Marketing Authorization by the European Commission, based upon the recommendation of the European Medicines Agency, which authorizes the COVID-19 Vaccine Moderna for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus in individuals 18 years of age and older.